scholarly journals Correction: Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides

Oncotarget ◽  
2019 ◽  
Vol 10 (34) ◽  
pp. 3203-3206
Author(s):  
Perry Tal ◽  
Shay Eizenberger ◽  
Elad Cohen ◽  
Naomi Goldfinger ◽  
Shmuel Pietrokovski ◽  
...  
Keyword(s):  
Therapeutic Approach ◽  
P53 Protein ◽  
Mutant P53 ◽  
Small Peptides ◽  
Conformational Stabilization

scholarly journals Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides

Oncotarget ◽  
2016 ◽  
Vol 7 (11) ◽  
pp. 11817-11837 ◽  
Author(s):  
Perry Tal ◽  
Shay Eizenberger ◽  
Elad Cohen ◽  
Naomi Goldfinger ◽  
Shmuel Pietrokovski ◽  
...  
Keyword(s):  
Therapeutic Approach ◽  
P53 Protein ◽  
Mutant P53 ◽  
Small Peptides ◽  
Conformational Stabilization

Human p53 and CDC2Hs genes combine to inhibit the proliferation of Saccharomyces cerevisiae

1992 ◽  
Vol 12 (3) ◽  
pp. 1357-1365
Author(s):  
J M Nigro ◽  
R Sikorski ◽  
S I Reed ◽  
B Vogelstein
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Growth Inhibition ◽  
Mammalian Cells ◽  
P53 Protein ◽  
Inducible Promoter ◽  
Mutant P53 ◽  
Wild Type ◽  
Growth Inhibitory Activity ◽  
Wild Type P53 ◽  
P53 Genes

Human wild-type and mutant p53 genes were expressed under the control of a galactose-inducible promoter in Saccharomyces cerevisiae. The growth rate of the yeast was reduced in cells expressing wild-type p53, whereas cells transformed with mutant p53 genes derived from human tumors were less affected. Coexpression of the normal p53 protein with the human cell cycle-regulated protein kinase CDC2Hs resulted in much more pronounced growth inhibition that for p53 alone. Cells expressing p53 and CDC2Hs were partially arrested in G1, as determined by morphological analysis and flow cytometry. p53 was phosphorylated when expressed in the yeast, but differences in phosphorylation did not explain the growth inhibition attributable to coexpression of p53 and CDC2Hs. These results suggest that wild-type p53 has a growth-inhibitory activity in S. cerevisiae similar to that observed in mammalian cells and suggests that this yeast may provide a useful model for defining the pathways through which p53 acts.

scholarly journals Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop

2011 ◽  
Vol 19 (1) ◽  
pp. 180-183 ◽  
Author(s):  
G Blandino ◽  
W Deppert ◽  
P Hainaut ◽  
A Levine ◽  
G Lozano ◽  
...  
Keyword(s):  
P53 Protein ◽  
Mutant P53 ◽  
Master Regulator

Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone

1993 ◽  
Vol 119 (3) ◽  
pp. 172-178 ◽  
Author(s):  
Yoshimichi Ueda ◽  
Barbara Dockhorn-Dworniczak ◽  
Sebastian Blasius ◽  
Walter Mellin ◽  
Paul Wuisman ◽  
...  
Keyword(s):  
P53 Protein ◽  
Mutant P53 ◽  
Benign Lesions

scholarly journals ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells

Oncotarget ◽  
2016 ◽  
Vol 8 (4) ◽  
pp. 5823-5833 ◽  
Author(s):  
Dun Li ◽  
Natalia D. Marchenko
Keyword(s):  
Cancer Cells ◽  
P53 Protein ◽  
Mutant P53

Mutant p53 protein associated with chemosensitivity in breast cancer specimens

The Lancet ◽  
1994 ◽  
Vol 344 (8937) ◽  
pp. 1647-1648 ◽  
Author(s):  
OssiR. Koechli ◽  
GabrielN. Schaer ◽  
Burkhart Seifert ◽  
René Hornung ◽  
Urs Haller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
P53 Protein ◽  
Mutant P53

Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease

1994 ◽  
Vol 25 (11) ◽  
pp. 1228-1233 ◽  
Author(s):  
Elina T. Eriksson ◽  
Hendrik Schimmelpenning ◽  
Ulla Aspenblad ◽  
Anders Zetterberg ◽  
Gert U. Auer
Keyword(s):  
Dna Content ◽  
Nuclear Dna ◽  
P53 Protein ◽  
Nuclear Dna Content ◽  
Breast Disease ◽  
Mutant P53 ◽  
Immunohistochemical Expression ◽  
Malignant Breast
Sign in / Sign up

Export Citation Format

Share Document